Samsca

Otsuka has launched Samsca (tolvaptan) for the treatment of hyponatraemia secondary to SIADH.

Tolvaptan is a selective vasopressin V2-receptor antagonist that binds to the receptor with a greater affinity than the arginine vasopressin found in the body. This causes an increase in urine excretion resulting in increased aquaresis, decreased urine osmolarity and increased serum sodium levels.

Care should be taken in patients with diabetes mellitus, urinary outflow obstruction and those at risk of demyelinisation syndromes. Fluid and electrolyte status should be closely monitored.

View Samsca drug record

Further information: Otsuka

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Stop withdrawal of bipolar disorder treatment, health secretary urged

Stop withdrawal of bipolar disorder treatment, health secretary urged

GPs, pharmacists, psychiatrists and patients are calling...

Contraception advice incentive for GPs linked to 'profound' reduction in abortions

Contraception advice incentive for GPs linked to 'profound' reduction in abortions

A scheme offering GPs financial incentives to provide...